Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13105230 | 1.00 | GBA1 (0.56) | GBA1HTR2CFUCA1PYGLALDH1A1 | |
| SCHEMBL3371156 | 1.00 | GBA1 (0.56) | GBA1HTR2CFUCA1PYGLALDH1A1 | |
| SCHEMBL2930728 | 0.87 | RORC (0.49) | GBA1HTR2CFUCA1 | |
| SCHEMBL2930730 | 0.87 | RORC (0.49) | GBA1HTR2CFUCA1 | |
| SCHEMBL14759416 | 0.83 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL14759418 | 0.83 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL1190716 | 0.83 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL742926 | 0.83 | GBA1 (0.75) | GBA1FUCA1S1PR1S1PR5 | |
| SCHEMBL9383279 | 0.77 | GBA1 (0.58) | GBA1FUCA1ALDH1A1S1PR1S1PR5 | |
| SCHEMBL3369882 | 0.76 | GBA1 (0.51) | GBA1ALDH1A1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | GBA1 1341/4885HTR2C 1175/4885FUCA1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.